Abbott India Ltd (ABBOTINDIA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Abbott India enters its Q1 FY27 results with a focus on sustaining growth across its portfolio of chronic care brands while navigating a more challenging currency environment. Investors will be watching for the initial revenue contribution from the newly launched GLP-1 therapy, Extensior, and management's commentary on maintaining margin quality amid rising employee costs and rupee depreciation.

Abbott India Ltd Q1 Results Date and Time

The board meeting is scheduled for August 12, 2026, to consider the unaudited Q1 FY27 financial results.

What to expect from Abbott India Ltd's Q1 FY27 results

Abbott India's revenue is expected to track in-line with its recent 6–8% YoY growth trend, though a sequential dip from the seasonally strong Q4 FY26 is anticipated. While the broader Indian Pharmaceutical Market shows 11.3% growth for 2026, Abbott’s defensive, chronic-focused portfolio remains the primary driver of its steady performance. EBITDA margins are likely to remain in the 31.5–32.0% range, as the company faces a structural margin drag from employee costs, which grew 13.8% in FY26, alongside a ~8.3% YoY rupee depreciation that increases the cost of imported stock. Management's ability to preserve these margins will depend on the extent to which high inventory levels—at 90.4 days—buffer the immediate impact of the weaker currency. The upcoming call will likely focus on the early adoption of the GLP-1 therapy Extensior and the company's progress in expanding its reach into Tier 2 and Tier 3 markets.

Key Things To Watch

Extensior (GLP-1) launch status: Monitoring the first full quarter of contribution for the new semaglutide offering.

• Initial prescription trends and doctor adoption among endocrinologists
• Competitive pricing dynamics in the GLP-1 segment
• Supply chain and pipeline commentary for the new therapy

EBITDA margin and cost structure: Assessing the impact of inflationary pressures on operating efficiency.

• Gross margin stability given the 90.4 days of inventory buffer
• Employee cost growth relative to revenue trajectory
• Impact of the 8.3% YoY rupee depreciation on imported stock-in-trade

Women's Health segment recovery: Tracking stabilization in a segment challenged by generic competition.

• Performance of the dydrogesterone segment following recent market stagnation
• Effectiveness of new product launches in offsetting competitive erosion

Working capital and inventory: Evaluating the sustainability of current inventory levels.

• Normalization of inventory days from the 90.4-day level seen at FY26 exit
• Sustainability of trade receivables days improvement to 19.54 days

Regulatory and market environment: Monitoring the impact of evolving price control frameworks.

• Management interpretation of the 13th DPCO amendment regarding separate pricing for specialized formats
• Competitive intensity across core GI, Metabolics, and Vaccine franchises